Pfizer Inks New CAR-T Deal, In Talks With P&G for Unit Sale – Nasdaq
Nasdaq |
Pfizer Inks New CAR–T Deal, In Talks With P&G for Unit Sale
Nasdaq Focus on the CAR-T area has increased with last year's FDA approval of therapies such as Novartis' NVS Kymriah and Gilead's Yescarta. These treatments have huge commercial potential and could well change the treatment paradigm. CAR-T falls under the … |
